Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janis M Taube

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Oncoimmunology|April 28, 2015
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockadeJanis M Taube
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Emerging immunologic biomarkers: setting the (TNM-immune) stageJanis M Taube
Oncoimmunology|October 10, 2015
Innate vs. Adaptive: PD-L1-mediated immune resistance by melanomaSneha Berry, Janis M Taube
Dermatology Online Journal|September 13, 2011
Pigmented extramammary Paget disease of the abdomen: a potential mimicker of melanomaJeremy Vincent, Janis M Taube
Current Opinion in Pharmacology|June 7, 2015
PD-1/PD-L1 inhibitorsJoel Sunshine, Janis M Taube
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2022
Data-Rich Spatial Profiling of Cancer Tissue: Astronomy Informs PathologyAlexander S Szalay, Janis M Taube
Pathology, Research and Practice|October 13, 2007
Multifocal ischemic necroses of varying age (MINOVA): A distinctive form of atherosclerotic heart diseaseJanis M Taube, Grover M Hutchins
Cancer Journal (Sudbury, Mass.)|January 24, 2018
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade TherapyTricia R Cottrell, Janis M Taube
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|January 9, 2003
Hospital ethics committees: formation, function, and case consultationThomas P Gonsoulin, Janis M Taube
JAMA Oncology|November 28, 2019
Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-ReplySteve Lu, Hao Wang, Janis M Taube
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Oncoimmunology|April 28, 2015
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockadeJanis M Taube
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Emerging immunologic biomarkers: setting the (TNM-immune) stageJanis M Taube
Oncoimmunology|October 10, 2015
Innate vs. Adaptive: PD-L1-mediated immune resistance by melanomaSneha Berry, Janis M Taube
Dermatology Online Journal|September 13, 2011
Pigmented extramammary Paget disease of the abdomen: a potential mimicker of melanomaJeremy Vincent, Janis M Taube
Current Opinion in Pharmacology|June 7, 2015
PD-1/PD-L1 inhibitorsJoel Sunshine, Janis M Taube
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2022
Data-Rich Spatial Profiling of Cancer Tissue: Astronomy Informs PathologyAlexander S Szalay, Janis M Taube
Pathology, Research and Practice|October 13, 2007
Multifocal ischemic necroses of varying age (MINOVA): A distinctive form of atherosclerotic heart diseaseJanis M Taube, Grover M Hutchins
Cancer Journal (Sudbury, Mass.)|January 24, 2018
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade TherapyTricia R Cottrell, Janis M Taube
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|January 9, 2003
Hospital ethics committees: formation, function, and case consultationThomas P Gonsoulin, Janis M Taube
JAMA Oncology|November 28, 2019
Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-ReplySteve Lu, Hao Wang, Janis M Taube
Pageof 18